Travere Therapeutics (TVTX) Competitors $17.38 +0.24 (+1.40%) (As of 10:52 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TVTX vs. TGTX, VKTX, BBIO, CRNX, KRYS, ACLX, ADMA, RARE, APLS, and BHVNShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), Krystal Biotech (KRYS), Arcellx (ACLX), ADMA Biologics (ADMA), Ultragenyx Pharmaceutical (RARE), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Krystal Biotech Arcellx ADMA Biologics Ultragenyx Pharmaceutical Apellis Pharmaceuticals Biohaven Travere Therapeutics (NASDAQ:TVTX) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, community ranking, earnings and profitability. Does the media prefer TVTX or TGTX? In the previous week, TG Therapeutics had 3 more articles in the media than Travere Therapeutics. MarketBeat recorded 5 mentions for TG Therapeutics and 2 mentions for Travere Therapeutics. TG Therapeutics' average media sentiment score of 1.47 beat Travere Therapeutics' score of 1.10 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TVTX or TGTX more profitable? TG Therapeutics has a net margin of -5.42% compared to Travere Therapeutics' net margin of -172.75%. TG Therapeutics' return on equity of -8.32% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-172.75% -537.74% -55.65% TG Therapeutics -5.42%-8.32%-3.40% Do analysts prefer TVTX or TGTX? Travere Therapeutics presently has a consensus price target of $23.67, indicating a potential upside of 38.08%. TG Therapeutics has a consensus price target of $40.67, indicating a potential upside of 21.14%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Travere Therapeutics is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more risk & volatility, TVTX or TGTX? Travere Therapeutics has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Do insiders & institutionals believe in TVTX or TGTX? 58.6% of TG Therapeutics shares are owned by institutional investors. 4.1% of Travere Therapeutics shares are owned by company insiders. Comparatively, 10.5% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, TVTX or TGTX? TG Therapeutics has higher revenue and earnings than Travere Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Travere Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$203.45M6.58-$111.40M-$4.55-3.77TG Therapeutics$264.79M19.74$12.67M-$0.10-335.70 Does the MarketBeat Community prefer TVTX or TGTX? TG Therapeutics received 580 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 76.57% of users gave TG Therapeutics an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% TG TherapeuticsOutperform Votes65776.57% Underperform Votes20123.43% SummaryTG Therapeutics beats Travere Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.37B$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-3.7710.75135.1817.54Price / Sales6.58287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book6.425.394.884.92Net Income-$111.40M$152.04M$118.97M$225.78M7 Day Performance-8.24%-4.32%15.73%-1.58%1 Month Performance-1.44%2.80%15.69%6.67%1 Year Performance107.51%17.30%34.73%22.48% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.7278 of 5 stars$17.38+1.4%$23.67+36.2%+97.9%$1.36B$203.45M-3.82460Positive NewsTGTXTG Therapeutics3.8158 of 5 stars$34.56+7.9%$40.67+17.7%+81.7%$5.38B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2712 of 5 stars$47.94+1.9%$106.75+122.7%+147.1%$5.34BN/A-51.5620Gap DownBBIOBridgeBio Pharma4.7215 of 5 stars$27.75+0.9%$47.69+71.9%-29.3%$5.24B$217.77M-11.63400Analyst ForecastCRNXCrinetics Pharmaceuticals4.2151 of 5 stars$54.32+1.2%$70.82+30.4%+60.7%$5.04B$1.04M-14.39210Analyst ForecastShort Interest ↓Positive NewsKRYSKrystal Biotech4.3121 of 5 stars$171.41+4.7%$206.67+20.6%+46.0%$4.93B$50.70M92.45229Analyst ForecastACLXArcellx3.2007 of 5 stars$85.25+1.7%$105.93+24.3%+60.5%$4.61B$155.82M-118.03130ADMAADMA Biologics3.8605 of 5 stars$19.02+2.3%$21.25+11.7%+343.6%$4.50B$382.81M68.32530Short Interest ↓RAREUltragenyx Pharmaceutical4.5688 of 5 stars$46.05+0.6%$87.46+89.9%-2.2%$4.25B$434.25M-7.081,276APLSApellis Pharmaceuticals4.721 of 5 stars$33.99+2.4%$49.94+46.9%-34.5%$4.23B$396.59M-16.35702Analyst DowngradeShort Interest ↓Positive NewsBHVNBiohaven3.9351 of 5 stars$41.14+6.9%$63.00+53.1%+0.3%$4.16B$462.51M-4.11239Analyst ForecastNews Coverage Related Companies and Tools Related Companies TG Therapeutics Competitors Viking Therapeutics Competitors BridgeBio Pharma Competitors Crinetics Pharmaceuticals Competitors Krystal Biotech Competitors Arcellx Competitors ADMA Biologics Competitors Ultragenyx Pharmaceutical Competitors Apellis Pharmaceuticals Competitors Biohaven Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TVTX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
